Netherlands Pharma and Life Sciences Tax Guide

Innovation Box — 9% Effective Rate on Pharma IP

• What qualifies: The innovation box (innovatiebox) is a regime under Dutch corporate tax law (art. 12b Wet Vpb) that allows a 9% effective tax rate on qualifying IP income — instead of the standard 25.8%. For pharma, qualifying IP includes: patents granted by the European Patent Office (EPO) or Dutch Patent Office (Octrooicentrum Nederland), orphan drug designations (EU Orphan Medicinal Product designation under Regulation EC 141/2000), biosimilar formulations (with patent protection or a Dutch R&D declaration), and qualifying R&D declarations (RDA-verklaring) for non-patented but R&D-intensive pharmaceutical processes (e.g., novel drug delivery systems, biomarker identification methods, AI-driven drug discovery algorithms).
• Nexus ratio — the IP income limitation: Qualifying IP income is limited by the nexus ratio (nexusbreuk): ((qualifying R&D expenditure + qualifying outsourcing) × 1.3) / total IP expenditure. For pharma companies with substantial in-house R&D in the Netherlands, the nexus ratio is typically close to 100%. Companies that acquired IP from related parties in a tax-favourable migration transaction must exclude the acquisition cost from the numerator — reducing the nexus ratio proportionally. A company cannot elect into the innovation box for acquired IP without significant further R&D.
• Step-in and step-out rules: The innovation box applies only from the year the IP qualifies (when the patent is granted or the RDA-verklaring is issued). All R&D costs incurred before qualification are accumulated and amortised. When the IP is sold or the patent expires, the innovation box benefit ceases — but any remaining deferred income continues to benefit.
• Interaction with WBSO: The same R&D costs can generate both WBSO wage credits (a payroll tax reduction at source) and innovation box income (a corporate tax rate reduction on resulting IP income). This is a powerful combination — a Dutch pharma company can reduce its effective tax rate on qualifying drug income to as low as 5–10%. The WBSO credit is calculated on R&D wages; the innovation box applies to the gross IP income minus directly attributable costs.

WBSO — R&D Tax Credits for Drug Development

• Who qualifies: The WBSO (Wet Bevordering Speur- en Ontwikkelingswerk) is a Dutch R&D incentive providing a 40% discount on the first €350,000 of R&D wages (2026) and 50% discount for startups (WBSO-subsidie in the first 5 years). Salary costs of researchers and technicians directly involved in drug development R&D are eligible. Overhead costs (lab consumables, equipment depreciation) are not directly covered but can be allocated to R&D projects via the WBSO project cost sheet.
• Qualifying R&D activities: In pharmaceuticals, qualifying activities include: (a) developing new active pharmaceutical ingredients (APIs) and novel chemical entities, (b) developing cell and gene therapies (CAR-T, AAV vectors, CRISPR), (c) preclinical formulation development (novel drug delivery, bioavailability enhancement), (d) AI/ML drug discovery algorithms, (e) developing medical devices with integral software, and (f) novel biomarkers and companion diagnostic development. Routine clinical trial management, data monitoring, and biostatistics without technical uncertainty do not qualify for WBSO.
• Application process — pre-approval required: The WBSO application must be filed with the Rijksdienst voor Ondernemend Nederland (RVO) before the R&D project begins. The application describes the technical R&D objectives, the technical uncertainties, and the planned activities. RVO reviews and issues a WBSO declaration (S&O-verklaring). The company uses the declaration to reduce its payroll tax remittances. Late applications (after project start) are rejected.
• RDA (Research and Development Deduction) — other costs: In addition to WBSO, the RDA (RDA-aftrek) provides an additional corporate tax deduction for R&D costs not covered by WBSO — lab equipment, consumables, research subcontracting (CRO costs). The RDA allows a 45.5% deduction on top of the normal cost deduction. The maximum combined WBSO + RDA benefit is significant — a mid-sized pharma company can reduce its effective R&D cost by 25–40%.

Clinical Trials — VAT Treatment

• Zorgvrijstelling (healthcare exemption): Clinical trials conducted as part of healthcare provision (diagnosis, treatment, or medical care) are exempt from VAT (vrijgesteld) under the zorgvrijstelling. This includes trials where patients are treated under a clinical protocol and the trial is managed by a hospital or academic medical centre (UMC). The sponsoring pharma company cannot recover input VAT on the clinical trial costs — this is a significant embedded VAT cost typically absorbed by the sponsor.
• Sponsor-led trials — deemed supplies: When a pharma company sponsors a clinical trial and provides the investigational medicinal product (IMP) free of charge to the hospital, the supply of the IMP may be treated as a deemed supply for VAT purposes (art. 3 Wet OB). The deemed value is the manufacturing cost of the IMP. However, for most pharma-sponsored trials, the IMP supply is outside the scope of VAT (as a sample for testing, not a commercial supply) — subject to an advance ruling from the Belastingdienst.
• Participant payments: Payments to clinical trial participants (subject payments, travel reimbursement) are not subject to VAT. The participant is not supplying a taxable service. The payments may be taxable for the participant as income — but the Belastingdienst does not actively pursue clinical trial payments below €5,000 per year.
• Contract Research Organisations (CROs): CROs providing clinical trial management services (IQVIA, Syneos, ICON, PSI CRO) to pharma sponsors are generally subject to 21% VAT — clinical trial management is not within the zorgvrijstelling because the CRO is not directly providing patient care. If the sponsor and CRO are both established in the Netherlands, 21% Dutch VAT applies. If the sponsor is outside the Netherlands (B2B), the VAT is typically reverse-charged to the sponsor.

Royalty Withholding Tax

• Withholding tax at 25.8% (2026): The Netherlands imposes a 25.8% royalty withholding tax (bronbelasting) on outbound royalty and licence payments to related entities in low-tax jurisdictions (ETR < 9%) and listed non-cooperative jurisdictions (EU blacklist). This applies to payments made on or after 1 January 2021 (extended from 2026 to cover all low-tax jurisdictions, not just blacklisted ones, as part of the broader Dutch anti-abuse framework).
• EU EOR (Exit of Residency) and wholly-artificial-arrangement carve-out: The royalty withholding tax does not apply if the recipient is an EU/EEA entity and the arrangement is not a wholly-artificial arrangement (wholly-artificial arrangement test under EU case law). A wholly-artificial arrangement exists where the recipient has no real economic activity, no substance, and the arrangement's main purpose is tax avoidance. The Dutch Supreme Court (Hoge Raad) applies the Cadbury Schweppes test — an EU entity with genuine substance, staff, and premises is not wholly artificial, even if the structure was tax-motivated.
• Substance requirements for IP companies: To benefit from the EU carve-out or a tax treaty reduction, the Dutch IP company must have economic substance. Substance requirements (besluit 1e en 2e overleg): (a) at least 50% of board members reside in the Netherlands, (b) the board meetings are held in the Netherlands, (c) key decisions are made in the Netherlands, (d) the company's bank accounts are Dutch, (e) the accounting records are maintained in the Netherlands, (f) the company has qualified staff in the Netherlands, and (g) the company bears economic risk. For IP companies specifically, the substance requirements are even stricter — the company must have R&D staff, IP management personnel, and active decision-making on IP strategy in the Netherlands.

Transfer Pricing for Pharma Supply Chains

• Contract manufacturing arrangements: Dutch toll manufacturers (e.g., Patheon/Thermo Fisher in Groningen, API producers) are typically compensated on a cost-plus basis (5–12% margin) under Dutch transfer pricing rules. The royalty/licence fee for the drug IP is paid to the IP owner (which may be the Dutch innovation box company). The functional analysis must clearly separate manufacturing risk, marketing risk, and R&D risk.
• Dutch principal companies: Many global pharma groups operate a principal structure through a Dutch principal company (hoofdkantoor) that: (a) owns the IP via the innovation box, (b) contracts with CROs and CMOs globally, (c) bears the economic risk of drug development, and (d) enters into licence agreements with operating subsidiaries. The Dutch principal must have the entrepreneurial functions (strategic decision-making, risk management) to justify retaining the residual profit. Without substance, the principal may be recharacterised as a limited-risk distributor or contract service provider.
• APA and Advance Pricing Agreements: The Belastingdienst offers Advance Pricing Agreements (APAs) for pharma supply chain transactions. An APA provides upfront certainty on: transfer pricing methodology, profit allocation to the Dutch principal, royalty rates for outbound licences, and cost contribution arrangements (CCAs) for joint R&D. APA applications are filed with the Belastingdienst's APA team in Rotterdam. Processing time: 4–9 months.

Biosimilars and Orphan Drug Incentives

• Orphan drug regulatory incentives: Orphan medicinal product designation (EU Regulation EC 141/2000) provides: (a) 10-year market exclusivity in the EU, (b) protocol assistance from the EMA, (c) reduced EMA fees (90% reduction), and (d) national implementation support. The innovation box applies — orphan drug IP income qualifies for the 9% effective rate.
• Biosimilars market — tax-efficient structuring: Biosimilar developers (e.g., Samsung Bioepis, Sandoz, Celltrion) can structure their European operations through the Netherlands with: (a) innovation box on novel biosimilar formulations, (b) WBSO/RDA on R&D wage costs and non-wage costs, (c) low effective tax rate on IP royalty income, and (d) comprehensive treaty network for outbound royalty payments to parent companies in Korea, Switzerland, or the US.

For pharma company formation and fiscal unity structuring, see our Starting a Business Guide →. For cross-border licensing and IP holding, see our Tax Treaties Guide →. For VAT on pharmaceutical manufacturing, see our VAT/BTW Guide →. For innovation box conditions in full detail, see our Corporate Tax Guide →.